Flerie AB (FRA:1NP1) Volatility: 27.91% (As of Jun. 29, 2026)


FRA:1NP1 Flerie AB FRA:1NP1
27 GF Score
Price €1.71
! 1 Warning Sign
View Full Analysis

What is Flerie AB Volatility?

Flerie AB FRA:1NP1 27 Volatility is 27.91% as of Jun. 29, 2026. GuruFocus rates FRA:1NP1 with a GF Score™ of 27/100. The stock has 1 warning sign investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-29), Flerie AB's Volatility is 27.91%.

Flerie AB  (FRA:1NP1) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Flerie AB Volatility Related Terms

FRA:1NP1 vs VRTX, REGN, ALNY: Volatility Comparison

For the Biotechnology subindustry, Flerie AB's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Flerie AB Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Flerie AB's Volatility distribution charts can be found below:

* The bar in red indicates where Flerie AB's Volatility falls into.


FRA:1NP1
27GF Score
Flerie AB FRA:1NP1
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Flerie AB  (FRA:1NP1) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 27.91% mean?
Flerie AB (FRA:1NP1) has a Volatility of 27.91% as of Jun. 29, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Flerie AB and its competitors.
Is Flerie AB's Volatility too high?
Flerie AB's current Volatility is 27.91%. Overall, Flerie AB has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Flerie AB's Volatility compare to VRTX and REGN?
Flerie AB's Volatility of 27.91% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Flerie AB and its competitors. Flerie AB's current Volatility is 27.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Flerie AB stock overvalued right now?
Flerie AB (FRA:1NP1) has a current Volatility of 27.91%. The current Volatility is 27.91%. Flerie AB's overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Flerie AB (FRA:1NP1), the current Volatility is 27.91% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Flerie AB Business Description

Other Exchanges FLERIE:Sweden1NP1:Germany
Address Skeppsbron 16, Stockholm, SWE, 111 30
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. It operates in two segments The Product Development segment, and The Commercial Growth segment. The Product Development segment consists of early and mid-stage biotech and pharma companies advancing their products and technologies toward clinical proofof-concept and marketing approvals. The Commercial Growth segment consists of companies already selling products or services, showcasing their ability to generate increasing revenues ahead of reaching sustainable profitability.
27GF Score

Get the complete analysis for FRA:1NP1

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.71
Price